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Inhibitory heterotrimeric G proteins and the control of heart rate. The activation of cell sig-
naling pathways involving inhibitory heterotrimeric G proteins acts to slow the heart rate
via modulation of ion channels. A large number of Regulators of G protein signalings (RGSs)
can act as GTPase accelerating proteins to inhibitory G proteins and thus it is important to
understand the network of RGS\G-protein interaction. We will review our recent findings
on in vivo heart rate control in mice with global genetic deletion of various inhibitory G
protein alpha subunits.We will discuss potential central and peripheral contributions to the
phenotype and the controversies in the literature.
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INTRODUCTION
The pacemaker in the sinoatrial node (SAN) of the heart has
an intrinsic rate independent of autonomic innervation and this
leads to a measurement of “intrinsic” heart rate that is deter-
mined in practice by pharmacologically inhibiting the sympa-
thetic and parasympathetic systems. At the molecular level this
self-regenerating electrical activity arises from a membrane clock
and\or a calcium clock dependent on intracellular calcium release
events (Lakatta and DiFrancesco, 2009). This pacemaker activ-
ity can be modulated: increased sympathetic activity leads to
an increase in rate and an increase in vagal tone to a decrease.
The release of noradrenaline from sympathetic nerve endings or
the release of adrenaline from the adrenal medulla into the cir-
culation modulates SAN cells by binding to β-adrenoreceptors.
The stimulatory G protein is activated and this leads to stimula-
tion of adenylate cyclase and the generation of cyclic adenosine
monophosphate (cAMP). Increased cAMP can directly modu-
late the hyperpolarization-activated cation currents (Ih/I f) lead-
ing to increased pacemaker depolarization and rate. However,
increased cAMP can also activate protein kinase A (PKA), which
can modulate intracellular calcium-handling proteins such as
phospholamban and the ryanodine receptor to modulate rate.
However, the main focus of this review is on the inhibitory
events typified by the negative chronotropic response in the SAN
to vagal nerve efferent activation. Acetylcholine (ACh) released
from the vagus nerve binds to the muscarinic (M2) receptor, lead-
ing to the activation, and dissociation of inhibitory G protein
heterotrimers. The resulting βγ-dimer directly activates the G pro-
tein coupled inward rectifying potassium (GIRK) channel to cause
membrane hyperpolarization, slowing pacemaker depolarization,
and sinus rate. Furthermore, the activation of the inhibitory Gα
subunit will inhibit adenylate cyclase and thus modulate Ih/I f as
detailed above. Regulators of G protein signaling (RGS) proteins
interact with the inhibitory Gα subunit to switch off this pathway
through GTPase accelerating protein (GAP) activity and allow the
heterotrimer to reform. This process is summarized in Figure 1.
It has emerged from the SHIFT trial using ivabradine, an
inhibitor of Ih/I f , in addition to standard therapy that heart rate
per se may be an important risk factor in chronic heart failure
(Swedberg et al., 2010). Furthermore, autonomic precipitants are
well known for common arrhythmias such as atrial fibrillation
(AF) and ventricular tachyarrhythmia (see below). Thus the focus
in this review is an attempt to link physiological and pathophys-
iological function in the control of heart rate and rhythm with
the known molecular isoforms of the inhibitory G proteins and
RGSs. These proteins are widely distributed in the heart thus we
will consider not only their effects on heart rate but also what
electrical processes they might modulate in the atria, atrioventric-
ular node (AVN), and ventricles. One of the key approaches is
the use of genetically modified mice. However, these often have
global knockout of the relevant gene and this will mean deletion
of the signaling molecule in central circuits and peripheral nerves
of the autonomic nervous system. Thus we review the role of
inhibitory G proteins in the central circuits and peripheral limbs
of the autonomic nervous system, consider the limited informa-
tion available and experimental approaches by which this might
be investigated.
THE MOLECULAR NUTS AND BOLTS
We initially discuss this from a cardiac perspective but the role of
the nervous system is obviously important and this is addressed in
another section.
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FIGURE 1 | A simplified schematic for the mechanism of heart rate
regulation by inhibitory G proteins. Acetylcholine released from the
vagus nerve binds to the muscarinic (M2) receptor, which is coupled to the
inhibitory G protein. The βγ-dimer activates the G protein coupled inward
rectifying potassium (GIRK) channel to slow the sinus rate, decrease the
action potential duration and allow arrhythmia generation. Regulators of G
protein signaling (RGS) interact with the α-subunit to switch off this pathway
through GTPase accelerating protein activity and allow the heterotrimer to
reform. AC, adenylyl cyclase; cAMP, cyclic AMP; PKA, protein kinase A;
HCN, hyperpolarization-activated cyclic nucleotide-gated channel.
INHIBITORY G PROTEINS
There are four families of G proteins namely Gαi/o, Gαs, Gαq/11,
Gα12/13. The inhibitory G proteins (Gαi/o) are the most highly
expressed and predominant class followed by Gαs, Gαq/11 then
Gα12/13. The inhibitory G proteins themselves have multiple iso-
forms: Gαi1, Gαi2, Gαi3, and Gαo. The Gαo (“other”) isoform has
two splice variants GαoA and GαoB. Gαo is the predominant iso-
form in the brain whereas Gαi1, Gαi2, Gαi3 are highly homologous
and widely distributed in many tissues (Wettschureck and Offer-
manns, 2005). The inhibitory G proteins characteristically inhibit
adenylate cyclase activity and lower the concentration of cAMP
(Wong et al., 1991; Rudolph et al., 1996), however they also acti-
vate PI-3 kinase activity and directly regulate ion channel activity
(see below).
REGULATORS OF G PROTEIN SIGNALING
Regulators of G protein signaling proteins act to effectively inhibit
G protein signaling; they interact with the α-subunit and accel-
erate GTPase activity. Characteristically this family have a 120
amino acid conserved RGS domain, flanked by variable length
N- and C-terminals. Six main subfamilies of mammalian RGSs
are distinguished: R4, R7, R12, RA, RL, and RZ. The vast major-
ity of RGSs are GAPs for inhibitory G proteins but some have
activity to the Gq/11 family as well. They may also have other roles
in signaling (Hollinger and Hepler, 2002). There are more than
20 mammalian RGS isoforms and many of these are expressed to
some extent in the heart (Kardestuncer et al., 1998; Doupnik et al.,
2001; Owen et al., 2001; Wieland and Mittmann, 2003). For both
Gαi/o and RGSs the pattern of expression in conducting tissues,
atria, and ventricles and in specific cell types such as myocytes and
fibroblasts is not well delineated.
KEY ION CHANNELS
The current paradigm for the mechanism underlying SAN auto-
maticity involves a complex interaction between activity of the
voltage gated ion channels/exchangers in the plasma membrane
and the sarcoplasmic reticulum (SR) (Lakatta and DiFrancesco,
2009). The key membrane ion channel thought to be involved in
pacemaker setting is the Ih/I f channel (DiFrancesco, 2010), and
pacemaker activity is further modulated by K+, Na+, and Ca2+
currents. In addition, recent studies suggest that rhythmic local
calcium releases from the SR modulated by PKA also contribute
to pacemaker activity by activating inward Na+/Ca2+ exchanger
currents during late diastolic depolarization (Maltsev and Lakatta,
2008).
Thehyperpolarization-activated cyclic nucleotide (HCN)gated
cation current (Ih), also known as the “funny” current (I f), is a
non-specific cation conductance.Hyperpolarization and the bind-
ing of cAMP mediate activation of the channel. Thus inhibition
of adenylate cyclase can reduce the current and slow pacemaker
depolarization and heart rate. HCN4 is the major isoform present
in the heart and it is present solely in conducting tissues in
the healthy heart. There is not complete consensus on the rel-
ative roles of Ih/I f and GIRK, but it is thought about half the
negative chronotropic effect of muscarinic receptor activation is
due to each mechanism (Wickman et al., 1998; Gehrmann et al.,
2002).
GIRK channels (Kir3.x) are part of the family of inwardly rec-
tifying K+ channels. The subfamily has five members (Kir3.1–3.5)
with a heterotetramer of Kir3.1 and 3.4 constituting the cardiac
channel and is present in the atria and conducting tissues but
has little if any expression in the ventricle (Karschin et al., 1994;
Krapivinsky et al., 1995). The channel is characteristically activated
by ACh binding to muscarinic (M2) receptors leading to the com-
mon designation as IKACh. The increase in channel activity occurs
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because of a direct interaction of the Gβγ dimer, released from the
inhibitory G protein heterotrimer, with specific domains in the
N- and C-termini of the channel and as such is a paradigm for
βγ subunit mediated signaling (Logothetis et al., 1987). The cur-
rent is also stimulated via adenosine, sphingosine-1-phosphate,
and endothelin-A receptors in the heart (Ono et al., 1994, 2001;
Bösche et al., 2003; Ochi et al., 2006).
The L-type calcium current is the most prominent calcium
current in mammalian ventricular heart cells. The alpha subunit
is CaV1.2 (also known as α1C). It is classically regulated by phos-
phorylation by PKA and thus will be modulated by variations in
G protein coupled receptor pathways involving Gαs and Gαi/o.
For example, the activation of β1-adrenoreceptors by agonists
leads to up to a fourfold increase in current and shifts the voltage
dependence of activation and inactivation to more hyperpolarized
potentials (McCleskey et al., 1986; Hirayama and Hartzell, 1997).
Although ACh has no effect upon basal L-type calcium currents,
it antagonizes their increase on application of a catecholamine
(Fischmeister and Hartzell, 1986).
Other membrane and sarcolemmal ion currents modulated via
the cAMP/PKApathway can also play a role inmodulation of pace-
maker activity. For example, isoprenaline reduced action potential
duration (APD) and increased spontaneous action potential firing
rate in rabbit SAN cells by increasing the amplitude and causing
a negative shift in the activation of the total delayed rectifier K+
current (IK) in a PKA-dependent manner (Lei et al., 2000).
REDUNDANCY IN FUNCTION
It is clear then that there are a number of isoforms of inhibitory G
proteins and RGSs expressed in the heart and other tissues, which
have potentially overlapping functions. Thus the question is do
specific isoforms carry out unique physiological roles or does the
system have significant redundancy? For example, inhibitory G
proteins are characterized by their sensitivity to pertussis toxin,
which ADP ribosylates the proteins and uncouples them from
receptors. It is possible to engineer Gαi/o isoforms that are resis-
tant to the toxin and thus design experimental strategies in which
the isoforms can be selectively investigated. In our own work
using in vitro cellular systems, we were able to show that only
rarely would there be an absolute preference of a receptor for
an inhibitory G protein isoform: most G protein coupled recep-
tors couple well with a number of isoforms (Leaney and Tinker,
2000).
THE ROLE OF Gαi/O AND RGSS IN CONTROLLING HEART RATE
We studied the question of which inhibitory G protein isoform
in vivo governs heart rate modulation and dynamics using mice
with global KOof Gαi2,Gαi1, andGαi3 combined andGαo (Zuberi
et al., 2008). We analyzed heart rate dynamics in the time and fre-
quency domain with implanted telemetry probes in awake and
mobile mice. The influence of the autonomic system can be mea-
sured indirectly by the beat-to-beat variation of heart rate (“heart
rate variability,” HRV). In man R–R interval shows characteris-
tic patterns of variability with a low frequency (LF) component
(>6 s cycle length) determined by sympathetic and parasympa-
thetic drive and a high frequency (HF) component (2.5–6 s cycle
length) governed by parasympathetic input (Stauss, 2003). Such
analysis has also been applied to the mouse but there is less agree-
ment on the contribution of the different arms of the autonomic
nervous system to the frequency components (Thireau et al.,
2007). We found that Gαi2 deficient mice were generally tachy-
cardic with preservation of diurnal variation, had loss of HF power
in HRV analysis similar to that seen with GIRK channel blocker
TertiapinQ and with the muscarinic receptor blocker atropine
and an attenuated bradycardic response to the muscarinic ago-
nist carbachol. Mice with global deficiency in Gαi1,3 were similar
to WT but Gαo showed a different phenotype that is discussed
below. There is one conflicting study suggesting Gαo and not
Gαi2 is necessary in muscarinic mediated parasympathetic activ-
ity which may be due to methodological issues as the mice were
studied very early after probe implantation (Duan et al., 2007).
In keeping with our observations, mice with a G184S knockin
point mutation in the switch I region of Gαi2, preventing the
binding of RGS proteins and deactivation of Gαi2, had marked
enhancement of muscarinic agonist mediated bradycardia (Fu
et al., 2007).
Gαi2 and Gαo signaling has also been implicated in the mus-
carinic inhibition of β-adrenoreceptor activated voltage gated L-
type calcium channels in the heart. Using ventricular myocytes
isolated from global Gαi2 and Gαi3 knockout mice, Nagata et al.
(2000) demonstrated reduced calcium channel currents with car-
bachol following isoproterenol stimulation in Gαi3 knockout mice
and littermate controls but not in Gαi2 knockout mice. Using a
similar experimental strategy in Gαo knockout mice, Valenzuela
et al. (1997) demonstrated similar impaired muscarinic regula-
tion of L-type calcium channels in ventricular myocytes lacking
Gαo but no difference in potassium current compared to wild type
controls.
Differential coupling of G protein subtypes to adenosine A1
and muscarinic M2 receptor mediated heart rate slowing was also
demonstrated in vitro using RGS insensitive Gαo and Gαi2 ES
derived cardiomyocytes (Fu et al., 2006). The RGS insensitive Gαo
homozygous knockin cells demonstrated enhanced adenosine A1
and muscarinic M2 receptor mediated bradycardic responses. In
contrast, RGS insensitive Gαi2 homozygous knockin cells showed
enhanced responses to M2 but not A1 receptors. Blocking GIRK
channels largely abolished the mutation-induced enhancement of
the M2 receptor mediated response but had a minimal effect on
A1 responses.
Taken together, the evidence suggests that M2 mediated GIRK
channel activation is coupled preferentially to the Gαi2 subunit
whereas coupling to voltage gated L-type calcium channel appears
to be less specific with both Gαo and Gαi2 implicated.
There are two studies asking which individual RGS might be
important for heart rate control. Cifelli et al. (2008) suggested
RGS4 is likely to be the predominant RGS in the SAN. RGS4
mRNA levels were found to be higher in the SAN compared to
the atrium, conscious RGS4 null mice showed an increased brady-
cardic response to carbachol and isolated sinus node myocytes
from these mice have modified M2 receptor mediated KACh cur-
rents. More recently, RGS6 has been found to be highly expressed
in the heart, in particular in the SAN and AVN. Conscious and
anesthetized RGS6 null mice also show an increased bradycardic
response to carbachol. Perfused hearts demonstrated a similar
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phenomenon, together with the inhibition of spontaneous action
potential firing rates in the SAN, as well as atrioventricular block
(Yang et al., 2010). RGS6 deficient mice show impaired desen-
sitization and slower deactivation of the GIRK current in atrial
myocytes in response to agonist application (Posokhova et al.,
2010), confirming that RGS6 has GAP activity. Taken together,
the results indicate that RGS4 and RGS6 have an important
parasympathetic modulatory role in the SAN, preventing severe
bradycardia and that there is very little redundancy. It would be
interesting to know if the combined knockout has a more severe
phenotype.
ATRIAL FIBRILLATION
Atrial fibrillation is the most common cardiac arrhythmia and
affects at least 10% of the octogenarian population (Ho et al.,
1993; Benjamin et al., 1998). It is characterized by rapid, irregular,
and chaotic electrical excitation of the atria, where these can beat
300 times per minute in the human. The AVN has decremental
properties and prevents every beat from being conducted to the
ventricle. Despite this, the ventricular rate can still be rapid result-
ing in symptoms of palpitations, shortness of breath, and dizziness
and it can precipitate overt heart failure. There have been several
proposed mechanisms of AF. Classically, it has been suggested that
AF arises due to an atrial ectopic focus, a single re-entry circuit, or
multiple re-entrant circuits (Nattel, 2002). Amoremodern variant
of these mechanisms for AF involves the concept of rotors and spi-
ral waves (Jalife, 2003). A rotor is a stable rotating pattern around
a pivot point. This gives rise to a spiraling wavefront (spiral waves)
into the surrounding tissue. Such a rotor is thought to be present at
the pulmonary vein-left atrial junction, with spiral waves emanat-
ing into the atria, giving fibrillation. Catheter ablation producing
anatomical block between the pulmonary veins and left atrium
can terminate AF supporting this hypothesis (Haissaguerre et al.,
1998).
It has been said that “AF begets AF” (Wijffels et al., 1995). This
statement is an illustration of the remodeling that occurs once
AF has commenced. Indeed permanent AF is often preceded by
paroxysmal AF. Remodeling can take two forms: electrical, which
occurs as a result of AF itself and structural, which is associated
with congestive cardiac failure and other cardiac and extracar-
diac diseases predisposing to fibrosis. An increase in rate caused
by AF results in increased cellular calcium loading, which threat-
ens cell viability. Subsequently, the density of the L-type calcium
channel is reduced with a corresponding increase in the inward
rectifying potassium currents, leading to a decreased APD and
effective refractory period (ERP). This, in turn, promotes and
perpetuates the induction and maintenance of AF through mul-
tiple re-entrant circuits. These calcium-handling abnormalities
impair atrial contractility and can cause atrial dilatation, which
also promotes AF (Nattel et al., 2008). In contrast, patients with
congestive cardiac failure are thought to develop AF secondary
to a change in atrial architecture due to fibrosis, which interferes
with electrical conductance. Profibrotic signaling pathways have
been identified and these include angiotensin II, transforming
growth factor-β1 and platelet derived growth factor. Extracardiac
disease, such as diabetes, obesity, and sleep apnea, may also be
responsible for an increased risk of AF through fibrosis. Atrial
stretch, which can occur secondary to mitral valve disease, is
also a known trigger. Genetic factors may contribute to remod-
eling; gain-of-function mutations in the potassium channels and
loss-of-functionmutations in the L-type calcium channel can pro-
mote AF. Moreover, single nucleotide polymorphisms alongside
genes contributing to atrial integrity have been associated with AF,
for example, angiotensin-converting enzyme and PITX2 (Wakili
et al., 2011).
An imbalance in the autonomic system may increase the
propensity to AF. In 18 subjects with paroxysmal AF, vagal overac-
tivity was described as the precipitating factor. Here, each parox-
ysm was preceded by atrial coupling followed by a pause and
accompanied by slowing of the sinus rate (Coumel et al., 1978).
Changes in autonomic tone through the study of HRV has been
assessed in 77 patients with paroxysmal AF (Bettoni and Zimmer-
mann, 2002). This study showed that at least 20min prior to the
onset of paroxysmal AF, there was an initial increase in adrenergic
drive followed by a shift in autonomic tone such that increased
vagal tone dominated immediately before the onset of paroxysmal
AF. The effects of both cholinergic and β-adrenergic stimulation
and blockade were studied in the intact dog heart (Sharifov et al.,
2004). ACh and catecholamines, individually and in combination,
were infused into the heart via the sinus node artery. No electrical
stimulation was performed. Cholinergic stimulation was found
to be the main factor responsible for spontaneous AF initiation.
Adrenergic tone, however, was involved in modulating the initi-
ation and maintenance of cholinergically mediated AF. Further
evidence for the role of a vagal mechanism in paroxysmal AF was
demonstrated in patients undergoing circumferential pulmonary
vein ablation in whom complete vagal denervation was also per-
formed (Pappone et al., 2004). These patients had greater freedom
from AF.
Activation of GIRK current results in membrane hyperpolar-
ization, and shortening of APD and ERP. The change in atrial ERP
may predispose to the induction and maintenance of AF. Thus
any increased activity in inhibitory G protein signaling may pre-
dispose to AF. There is surprisingly little data mapping specific
genetic modifications in this pathway to experimental supraven-
tricular tachyarrhythmia. It is possible to induce non-sustainedAF
in the mouse using programmed electrical stimulation (Kovoor
et al., 2001). Patch clamp studies utilizing atrial cardiomyocytes
from humans (Dobrev et al., 2005) and dogs (Voigt et al., 2008)
illustrate that the GIRK channel is constitutively active in AF. Fur-
thermore, the Kir3.4 knockout mouse is resistant to AF (Kovoor
et al., 2001). Overexpression of Gαi2 using a viral vector has also
been tried as a therapeutic strategy (Bauer et al., 2004). Injec-
tion of the construct into the AVN of animals slowed the heart
rate in AF (Bauer et al., 2004). The delivery of cell penetrating
peptides to the posterior left atrium to disrupt M2-Gαi coupling
prolonged refractoriness in the left atrium and suppressed vagally
induced AF (Aistrup et al., 2009). It is interesting to note that it
was necessary to target both Gαi2 and Gαi3 here. Furthermore,
it has been shown that in Gαi2 knockout mice, where the hearts
are studied ex vivo, pacemaking occurs from the atria not the SAN
and there is no impairment of muscarinic receptor mediated heart
rate slowing (Boknik et al., 2009). This suggests that there may be
differences in the coupling profile between the M2 receptor and
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GIRK channel in the atria and SAN. Once again there is little
information on which RGSs might be important in the atria. Of
those studied functionally, RGS6 but not RGS4 is expressed there
and RGS10 mediates β-adrenergic receptor effects on the GIRK
current in rat atrial cells (Bender et al., 2008). There is one report
showing inducible AF in the RGS2 knockout mouse (Tuomi et al.,
2010).
VENTRICULAR ARRHYTHMIA
Ventricular cardiac arrhythmias, namely ventricular tachycardia
(VT) and ventricular fibrillation (VF), cause sudden cardiac death
(SCD). SCD poses a significant clinical burden with an estimated
300 000 cases per year recorded in the USA (Noseworthy and
Newton-Cheh, 2008). This highlights the importance in predict-
ing risk of SCD, although precise calculation of such a risk remains
challenging. Drug therapy, as in AF, can be limited by modest effi-
cacy, significant toxicity, and can be proarrhythmic. ICDs have
proven benefit but are complicated by inappropriate shocks, the
need for a generator and possible lead changes and complications
at the time of insertion, for example infection. Catheter ablation
is invasive and is suitable for only modest numbers of patients.
Therefore, there is a need to understand the molecular mecha-
nisms responsible for VT initiation and maintenance, in order to
develop successful treatments.
The etiology of VT/VF can be broadly divided into those occur-
ring in patients with structurally normal or abnormal hearts.
Normal heart VT/VF has traditionally been considered a pri-
mary electrical problem, caused by “channelopathies” including
the long QT (LQT) syndromes and Brugada syndrome. In some
cases, the cause of VT/VF is unknown and hence diagnosed as
idiopathic VT. Structurally abnormal hearts causing VT/VF can
be due to inherited conditions such as hypertrophic cardiomy-
opathy (HCM) and arrhythmogenic right ventricular cardiomy-
opathy (ARVC) or acquired cardiomyopathies, the most common
of which is ischemic cardiomyopathy.
Autonomic precipitants to VT/VF is well recognized clinically.
Both increased sympathetic and parasympathetic tone can lead
to VT/VF depending on etiology and the underlying electrical
abnormalities. For example, LQT 1 and 2 are precipitated by an
increase in sympathetic tone whereas in LQT 3, it is protective
(Moss and Kass, 2005). In Brugada syndrome, vagotonic agents
and β adrenergic blockers can precipitate VT/VF (Kasanuki et al.,
1997). In patients with idiopathic VT/VF and short coupled vari-
ant of torsades des pointes, HRV was significantly depressed prior
to the onset of ventricular tachyarrhythmia suggesting vagal pre-
cipitant (Leenhardt et al., 1994). The arrhythmogenic substrate
is thought to be due to the amplification of spatial dispersion
of repolarization by the underlying autonomic tone, causing
abnormal re-entry, or triggered activity (Verrier and Antzelevitch,
2004).
Bradycardia itself per se may precipitate polymorphic VT by
causing prolongation of APD and development of early afterdepo-
larizations, leading to triggered activity in the form of ventricular
premature beats (El-Sherif et al., 1988). Hence any perturba-
tion of Gαi/o signaling in the conduction system which leads to
bradycardia could in theory increase susceptibility to ventricular
arrhythmia.
In patients with ischemic cardiomyopathy induced VT/VF
and heart failure, the picture is somewhat different. Sympathetic
nervous system activation is beneficial acutely in heart failure
but detrimental in the long term. Such a mechanism promotes
apoptosis of cardiac myocytes, ion channel remodeling, and is
proarrhythmic (DeGeorge et al., 2008). Cardiac Gαi/o signal-
ing pathways may counteract this process (Zheng et al., 2005).
Indeed, in chronic heart failure, β1-adrenoceptors are downregu-
lated whereas Gαi2 is significantly increased (Eschenhagen et al.,
1992). Overexpression of β1-adrenoceptors in transgenic mice
results in a dilated cardiomyopathy but a more modest phenotype
is seenwithβ2-adrenoceptor overexpression.β2-adrenoceptors are
coupled to Gαi/o and Gαs, suggesting a cardioprotective role for
Gαi/o (Foerster et al., 2003; DeGeorge et al., 2008).
In heart failure patients with ICDs, a loss in HRV was noted
immediately before an episode of VT and this was found to be
an independent predictor of SCD (Pruvot et al., 2000). Parasym-
pathetic activation can terminate VT and increase VF threshold
whereas increases in sympathetic activation can precipitate ven-
tricular arrhythmias (Kolman et al., 1975; Waxman and Wald,
1977; Brack et al., 2007). Taken together, there is good evidence
that increased vagal tone protects against the development of heart
failure and VT/VF precipitated by ischemic cardiomyopathy. Cer-
tainly β-blocker therapy improves prognosis in those with heart
failure (Poole-Wilson et al., 2003).
To explore the role of Gαi2 and predisposition to cardiac
ventricular arrhythmias, we performed in vivo cardiac electro-
physiological studies on global Gαi2 knockout mice and com-
pared them with wild type littermates and combined Gαi1 and
Gαi3 knockout controls (Zuberi et al., 2010). Mice with global
genetic deletion of Gαi2 were found to have a reduced ventric-
ular effective refractive period and propensity for VT induced
with programmed electrical stimulation compared to controls.
Conscious Gαi2 knockout mice had a prolonged QT interval and
single ventricular myocytes studied with patch clamping showed
a steep restitution curve but prolonged APD. Increased levels
of message for the L-type calcium channel was found on gene
expression studies, with confirmation of an increase in this cur-
rent on patch clamping. No structural heart disease was noted
on histology or echocardiography. These findings suggest that the
absence of Gαi2 is a substrate for VT. Interestingly, Dizayee et al.
(2011) studied ventricular myocytes isolated from Gαi2 and Gαi3
knockout mice and found reduced L-type calcium channel cur-
rent density in Gαi2 knockouts compared to littermate controls
but increased in Gαi3 knockouts where there was a compen-
satory increase in Gαi2 expression. The differences between our
results and theirs may be accounted for by strain differences in
the mice (129\Sv versus C57\Black) Clinically, pravastatin, given
to patients in order to lower cholesterol, selectively upregulates
Gαi2 and increases HF power in HRV analysis (Welzig et al.,
2003).
REGULATION OF THE HEART BY THE AUTONOMIC NERVOUS
SYSTEM
The autonomic nervous system maintains homeostasis and coor-
dinates physiological responses in the body via its two functional
limbs: the sympathetic and parasympathetic nervous systems. The
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FIGURE 2 |The main peripheral and neural centers involved in
autonomic cardiovascular regulation. (A) Sympathetic baroreflex arm:
sensory neurons in the periphery transmit baroreceptor information via a
glutamatergic synapse to the nucleus tractus solitaries (NTS) in the
medulla. NTS neurons project to and excite neurons in the caudal
ventrolateral medulla (CVLM). CVLM neurons in turn project and inhibit (via
a GABAergic synapse) presympathetic neurons in the rostral ventrolateral
medulla (RVLM). Spinally projecting presympathetic RVLM neurons make
direct connections with sympathetic preganglionic neurons in the
intermediolateral (IML) spinal column, which projects sympathetic outflow
to effector organs. (B) Parasympathetic control of heart rate: NTS neurons
receive baroreceptor and chemoreceptor information and relay via a
glutamatergic pathway to the nucleus ambiguous (NA). Cardioinhibitory
neurons in NA then project to the heart via the vagus nerve, which
mediates its effect via muscarinic receptors in the heart. Adapted from
Pilowsky and Goodchild (2002). GABA, gamma-Aminobutyric acid; SA,
sinoatrial; AV, atrioventricular.
heart is regulated in this manner within the cardio-respiratory sys-
tem (Figure 2). Afferent nerves convey baroreceptor and chemore-
ceptor inputs to the cardio-respiratory centers within the brain-
stem and generally opposing reflex responses are mediated by
the sympathetic and parasympathetic efferent to the heart, blood
vessels, and other effector organs such as the adrenal glands.
Both sympathetic and parasympathetic systems are made up
of central and peripheral components. The central component
consists of cell groups in the brain and spinal cord, and myeli-
nated preganglionic neurons. It is responsible for maintenance
of autonomic tone, and integration of afferent inputs to gener-
ate appropriate autonomic reflexes. Much of the basic structure
involved in the reflex control of the cardiovascular system is
contained within the medulla. Integrated and behaviorally appro-
priate responses also require reciprocal connections between the
medulla, pons, midbrain, and hypothalamus (Spyer, 1994). The
peripheral component consists of ganglia and unmyelinated post-
ganglionic afferent and efferent fibers innervating the heart and
associated effector organs (e.g., blood vessels). It is increasingly
recognized that the pattern of cardiac innervation peripher-
ally may be important in cardiac arrhythmogenesis (Verrier and
Antzelevitch, 2004).
As described above, the murine models used to study
(patho)physiology are often global knockouts or knock-ins. It is
conceivable (and probably very likely) that there are contributions
to the phenotype from the effects on inhibitory G protein signal-
ing in the nervous system. Gαi1, Gαi2, and Gαi3 are ubiquitously
expressed but Gαo protein expression is restricted mainly to the
central and peripheral nervous systems, endocrine cells, and car-
diomyocytes (Wettschureck and Offermanns, 2005). Expression
of Gαo is greatest in the brain where it is estimated to constitute
around 1% of all membrane proteins (Sternweis and Robishaw,
1984). Mice lacking the α subunit of Go are smaller and weaker
than their littermates, have greatly reduced life expectancy and dis-
play numerous neurological abnormalities including hyperalgesia,
tremors, seizures, and increased motor activity with an extreme
turning behavior (Jiang and Bajpayee, 2009).
GIRK channels are widely distributed in neuronal and
endocrine tissues and play key roles in generating late inhibitory
postsynaptic potentials and modulating hormone release in addi-
tion to their cardiac functions. In the central nervous system,
GIRK channels hyperpolarize neurons in response to activa-
tion by neurotransmitters including adenosine, somatostatin, 5-
HT, and opioids, and is composed of heterotetramers of Kir3.1,
Kir3.2, and Kir3.3 and homotetramers of Kir3.2 (Lüscher et al.,
1997; Lüscher and Slesinger, 2010). Pharmacological investiga-
tions of GIRK channels and studies in animal models sug-
gest that GIRK activity has an important role in physiological
responses, including pain perception and memory modulation.
Abnormal GIRK function has been implicated in altering neu-
ronal excitability and cell death, which may be important in
the pathophysiology of diseases such as epilepsy, Down’s syn-
drome, Parkinson’s disease, and drug addiction (Lüscher and
Slesinger, 2010). There is limited study of GIRK’s role in auto-
nomic traffic. Feldman and colleagues found reduced BP depres-
sor effects of the I1-imidazoline receptor (I1R) selective ligands
administered intracisternally in rabbits pretreated with Tertiap-
inQ suggesting that the central sympatho-inhibitory effects of
I1R ligands are mediated by GIRK channels (Yoro Sy et al.,
2008).
The regulation of neurotransmitter release at presynaptic ter-
minals is an important mechanism underlying the modulation of
synaptic transmission in the nervous system. Inhibitory regulation
of neurotransmitter release via inhibitory G proteins is mediated
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by various G protein coupled receptors like α2-adrenoceptors, μ-
and δ-opioid receptors,GABA-B receptors, adenosineA1,or endo-
cannabinoid CB1-receptors. A major mechanism by which these
G proteins mediate the inhibition of transmitter release is the
direct inhibitory modulation of the action potential-evoked Ca2+
entry to the presynaptic terminal by the Gβγ subunit, which is
required to trigger neurotransmitter release. N- and P/Q-type cal-
cium channels that are concentrated at nerve terminals as well
as R-type calcium channels have been shown to be inhibited via
Gαi/o-coupled receptors (Dolphin, 2003).
There is evidence showing selectivity of inhibitory G protein
coupling to voltage gated Ca2+ channels. Neuropeptide Y (NPY)
and bradykinin both inhibit N-type Ca2+ channels in vitro, and
pertussis toxin treatment could completely abolish this inhibition.
Addition of purified bovine Gαo subunits effectively restored the
NPY modulation of Ca2+ currents while purified Gαi1 or Gαi2 had
little or no effect. Interestingly, the bradykinin inhibitory effects
on Ca2+ currents in pertussis toxin-treated cells was only par-
tially restored by the addition of either purified Gαo or Gαi2, even
at high concentrations. Complete restoration required a combi-
nation of both Gαo and Gαi2 proteins suggesting that Gαo and
Gαi2 proteinsmay couple to distinct subpopulations of bradykinin
receptors since Gαo nor Gαi2 protein alone cannot compensate
the loss of the other (Ewald et al., 1989). Gαo antibodies in the
superior cervical ganglion has also been shown to reduce cal-
cium current inhibition by noradrenaline in superior cervical
ganglion neurons (Caulfield et al., 1994). Signaling via Gαo has
also been implicated in vesicular glutamate transporter within
the central nervous system (Winter et al., 2005) and GAP43
receptor signaling for neuronal pathfinding (Strittmatter et al.,
1990).
In vivo experiments manipulating the expression of inhibitory
G proteins and its subtypes either directly with knockout mod-
els or indirectly by manipulation of their regulatory proteins have
shed limited light on their physiological importance and relative
contribution to the peripheral and central control of autonomic
heart rate regulation. Methodologically, autonomic tone in vivo
has been quantified by indirect methods such as catecholamine
sampling and analysis of HRV. The baroreceptor reflex is the pro-
totypical cardiovascular reflex studied and is commonly quantified
by computation of baroreflex set point and gain from ambulatory
BP recordings, although more direct methods have been described
(Ma et al., 2002; Young and Davisson, 2011).
Interestingly, mice overexpressing RGS insensitive Gαi2 were
tachycardic during the daytime, have an enlarged heart and
hyperdynamic echo profile. Along with reduced viability, growth
retardation, and multiple neurological deficit, the cardiovascular
phenotype observed was attributed to increased central sympa-
thetic tone (Huang et al., 2006). To study the cardiac specific
effect of enhanced Gαi2 signaling, isoproterenol-stimulated beat-
ing isolated perfused hearts were studied and showed the expected
enhancement of muscarinic mediated bradycardia (Fu et al.,
2007).
Mice deficient in RGS2 were found to be hypertensive but
with normal HR suggestive of resetting of baroreceptor sensi-
tivity. There was an associated increase in urinary catecholamine
secretion and reduction in both LF and HF power of HRV suggest-
ing increased central sympathetic tone (Gross et al., 2005). This
along with data on the RGS insensitive Gαi2 mice described above
implies that overactivity of inhibitory G proteins may contribute
to increased central sympathetic tone. In our study of global Gαo
knockout mice (Zuberi et al., 2008), in addition to the neurolog-
ical abnormalities previously described, we found the mice to be
tachycardic with loss of diurnal rhythm and fairly selective loss of
the LF component of HRV with preserved total power. However,
carbachol still had a negative chronotropic effect. This is suggestive
of increased sympathetic tone, likely to be of central origin.
Significant progress has been made in our understanding of the
autonomic nervous system and the effects upon cardiac function.
Nonetheless, further study of the chronic alterations in the auto-
nomic nervous system and their cardiac consequences may prove
useful in the prevention of cardiac disease and provide valuable
treatment modalities (Brodde and Michel, 1999).
CONCLUSION AND FUTURE DIRECTIONS
It is clear that inhibitory G proteins and their associated RGS pro-
teins play a critical role in autonomic signaling at multiple levels.
Their role in mediating the parasympathetic tone to the heart is
well established.What is unclear is their role in autonomic traffic in
the central autonomic circuits. This will need further elucidation
to dissect the role of autonomic tone in cardiac pathophysiol-
ogy. What is also unclear is what role the autonomic nervous
system and the specific signaling molecules have in generating
cardiac arrhythmia. Mice with global G protein deletion often
have reduced viability and are difficult to work with and it can be
unclear at which level signaling is contributing to the phenotype.
Use of more refined temporal and spatial conditional deletion
strategies would circumvent some of the problems and help define
the relative role of inhibitory G proteins and its subtypes in the
central and peripheral autonomic control of the heart.
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